Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Quick facts
Marketed products
- daptomycin and gentamicin
- daptomycin (up to 14 days) · Infectious Disease
Daptomycin binds to bacterial cell membranes and causes rapid depolarization, leading to loss of essential ions and bacterial cell death. - Semi-Synthetic Penicillin · Infectious Disease
Semi-synthetic penicillins inhibit bacterial cell wall synthesis by binding to penicillin-binding proteins and blocking peptidoglycan cross-linking.
Phase 3 pipeline
- Alviompan · Other
- CB-183,315 · Infectious Disease
CB-183,315 is a selective inhibitor of bacterial protein synthesis that targets gram-positive pathogens by binding to the bacterial ribosome. - CXA-201 · Infectious Disease
CXA-201 is a novel antibiotic that inhibits bacterial protein synthesis by targeting the ribosome. - CXA-201 and metronidazole · Infectious Disease
CXA-201 is a non-absorbed topical antibiotic that works synergistically with metronidazole to treat bacterial infections, particularly in the gastrointestinal tract or as a topical agent. - Nafcillin (or equivalent) · Infectious Disease
Nafcillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. - Tedizolid Phophate · Infectious Diseases
Tedizolid phosphate is an oxazolidinone antibiotic that inhibits protein synthesis in bacteria by binding to the 50S ribosomal subunit. - Vancomycin (or equivalent) · Infectious Diseases
Vancomycin inhibits cell wall synthesis in Gram-positive bacteria by binding to the D-alanyl-D-alanine terminus of cell wall precursors.
Phase 2 pipeline
- ADL5859 · Infectious Diseases
ADL5859 is a small molecule antibiotic that targets the bacterial cell wall synthesis. - CXA-101 · Infectious Diseases
CXA-101 is a siderophore antibiotic that targets bacterial iron acquisition.
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) portfolio CI brief
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) pipeline updates RSS
Frequently asked questions about Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
What are Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)'s marketed drugs?
Top marketed products include daptomycin and gentamicin, daptomycin (up to 14 days), Semi-Synthetic Penicillin.
What is Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)'s pipeline?
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) has 7 drugs in Phase 3, 2 in Phase 2, 1 in Phase 1. Late-stage candidates include Alviompan, CB-183,315, CXA-201, CXA-201 and metronidazole.
Related
- daptomycin and gentamicin
- daptomycin (up to 14 days) · Infectious Disease
- Semi-Synthetic Penicillin · Infectious Disease
- Sector hub: All tracked pharma companies